Skip Navigation

Publication Detail

Title: Cannabinoid Receptor Activation on Haematopoietic Cells and Enterocytes Protects against Colitis.

Authors: Becker, William; Alrafas, Haider Rasheed; Busbee, Philip B; Walla, Michael D; Wilson, Kiesha; Miranda, Kathryn; Cai, Guoshuai; Putluri, Vasanta; Putluri, Nagireddy; Nagarkatti, Mitzi; Nagarkatti, Prakash S

Published In J Crohns Colitis, (2021 Jun 22)

Abstract: BACKGROUND AND AIMS: Cannabinoid receptor [CB] activation can attenuate inflammatory bowel disease [IBD] in experimental models and human cohorts. However, the roles of the microbiome, metabolome, and the respective contributions of haematopoietic and non-haematopoietic cells in the anti-colitic effects of cannabinoids have yet to be determined. METHODS: Female C57BL/6 mice were treated with either cannabidiol [CBD], Δ 9-tetrahydrocannabinol [THC], a combination of CBD and THC, or vehicle, in several models of chemically induced colitis. Clinical parameters of colitis were assessed by colonoscopy, histology, flow cytometry, and detection of serum biomarkers; single-cell RNA sequencing and qRT-PCR were used to evaluate the effects of cannabinoids on enterocytes. Immune cell transfer from CB2 knockout mice was used to evaluate the contribution of haematopoietic and non-haematopoietic cells to colitis protection. RESULTS: We found that THC prevented colitis and that CBD, at the dose tested, provided little benefit to the amelioration of colitis, nor when added synergistically with THC. THC increased colonic barrier integrity by stimulating mucus and tight junction and antimicrobial peptide production, and these effects were specific to the large intestine. THC increased colonic Gram-negative bacteria, but the anti-colitic effects of THC were independent of the microbiome. THC acted both on immune cells via CB2 and on enterocytes, to attenuate colitis. CONCLUSIONS: Our findings demonstrate how cannabinoid receptor activation on both immune cells and colonocytes is critical to prevent colonic inflammation. These studies also suggest how cannabinoid receptor activation can be used as a preventive and therapeutic modality against colitis.

PubMed ID: 33331878 Exiting the NIEHS site

MeSH Terms: Animals; Cannabidiol/pharmacology*; Cannabinoid Receptor Agonists/pharmacology; Colitis*/chemically induced; Colitis*/metabolism; Colitis*/pathology; Colitis*/therapy; Colonoscopy/methods; Dronabinol/pharmacology*; Drug Monitoring; Enterocytes*/drug effects; Enterocytes*/metabolism; Enterocytes*/pathology; Gastrointestinal Microbiome/drug effects; Gastrointestinal Microbiome/immunology; Immunity, Cellular*/drug effects; Immunity, Cellular*/physiology; Mice; Mice, Inbred C57BL; Mice, Knockout; Protective Agents/pharmacology; Receptor, Cannabinoid, CB2*/genetics; Receptor, Cannabinoid, CB2*/metabolism

Back
to Top